1. Teerlink JR, Bourge RC, Cleland JGF, Jondeau G, Krum H, Metra M, et al. Effects of tezosentan on symptoms. Heart Fail. 2009;298:2009–19.
2. Prasad SK, Dargie HJ, Smith GC, Barlow MM, Grothues F, Groenning BA, et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart [Internet]. 2006;92:798–803. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16339819%5 , http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1860639 .
3. Anand PI, McMurray PJ, Cohn PJN, Konstam PMA, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347–54.
4. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–602.
5. McMurray JJV, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med [Internet]. 2016;374:1521–32. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1514859%5 , http://www.ncbi.nlm.nih.gov/pubmed/27043774 .